Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 6—June 2021
Research

Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201

Kirsten E. Wiens, Pinyi Nyimol Mawien, John Rumunu, Damien Slater, Forrest K. Jones, Serina Moheed, Andrea Caflisch, Bior K. Bior, Iboyi Amanya Jacob, Richard Lino Lako, Argata Guracha Guyo, Olushayo Oluseun Olu, Sylvester Maleghemi, Andrew Baguma, Juma John Hassen, Sheila K. Baya, Lul Deng, Justin Lessler, Maya N. Demby, Vanessa Sanchez, Rachel Mills, Clare Fraser, Richelle C. Charles2, Jason B. Harris2, Andrew S. Azman3Comments to Author , and Joseph F. Wamala3
Author affiliations: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (K.E. Wiens, F.K. Jones, J. Lessler, M.N. Demby, A.S. Azman); Republic of South Sudan Ministry of Health, Juba, South Sudan (P.N. Mawien, J. Rumunu, B.K. Bior, I.A. Jacob, R.L. Lako, L. Deng); Massachusetts General Hospital, Boston, Massachusetts, USA (D. Slater, S. Moheed, V. Sanchez, R. Mills, C. Fraser, R.C. Charles, J.B. Harris); International Organization for Migration, Juba (A. Caflisch); World Health Organization, Juba (A.G. Guyo, O.O. Olu, S. Maleghemi, A. Baguma, J.J. Hassen, S.K. Baya, J.F. Wamala); Kabale University School of Medicine, Kabale, Uganda (A. Baguma); Harvard Medical School, Boston (R.C. Charles, J.B. Harris); Médecins Sans Frontières, Geneva, Switzerland (A.S. Azman); Institute of Global Health, Geneva (A.S. Azman)

Main Article

Table 2

Crude seropositivity, adjusted seroprevalence, and relative risk of seropositivity by age and sex from survey of seroprevalence of SARS-CoV-2 IgG in Juba, South Sudan.*

Category No. No. (%) positive No. (%) negative Seroprevalence (95% CrI) Relative risk (95% CrI)
Overall
 1,840
 411 (22.3)
 1,429 (77.7)
 38.3 (31.8–46.5)
Age, y
1–4 68 20 (29.4) 48 (70.6) 43 (31.3–56.1) 1.30 (0.96–1.71)
5–9 224 52 (23.2) 172 (76.8) 39.3 (29.5–51.1) 1.19 (0.92–1.51)
10–19 448 124 (27.7) 324 (72.3) 44.9 (36.3–56) 1.36 (1.11–1.66)
20–29 459 89 (19.4) 370 (80.6) 33.3 (25.6–42) Referent
30–39 307 52 (16.9) 255 (83.1) 30 (21.9–39.3) 0.91 (0.68–1.17)
40–49 139 26 (18.7) 113 (81.3) 33.2 (22.8–45.6) 1.00 (0.71–1.35)
50–64 120 31 (25.8) 89 (74.2) 42.8 (30.6–57.6) 1.29 (0.94–1.73)
65–84
 75
 17 (22.7)
 58 (77.3)
 38.8 (25.2–54.8)
 1.17 (0.78–1.63)
Sex
F 1,149 260 (22.6) 889 (77.4) 33.3 (25.6–42) Referent
M 691 151 (21.9) 540 (78.1) 31.7 (23.6–41.2) 0.95 (0.81–1.12)

*NA, not available; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Main Article

1A portion of this research was presented at the United States–Japan Cooperative Medical Sciences Program—Virtual Workshop on COVID-19, February 24–26, 2021.

2These authors contributed equally to this article.

3These authors contributed equally to this article.

Page created: March 25, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external